‘Inertia’ Likely To Restrain Biosimilar Humira In US Market, Experts Say
PBM contracting and payer formulary placement for branded Humira signal headwinds for biosimilar versions in the US, according to participants in an IQVIA-sponsored panel.
You may also be interested in...
Witnesses at a US Senate Finance Committee Hearing have condemned the impact the “perverse” practices of pharmacy benefit managers have on off-patent drugs, often placing them on non-preferred tiers so that patients must use more expensive, branded medication.
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.
With adalimumab biosimilars now on market in the US, AbbVie said it expects sales erosion this year toward the lower end of its previous guidance, with pricing comprising the larger portion of the hit.